Aptevo Therapeutics Inc. (FWB:AP82) Financings
Financings
| Raise | Date |
|---|---|
| Warrant exercise of common stock on exercise of existing warrants Closed: US$3M raised · US$1.08 a share · Warrants at US$1.08 for 60 months · Roth Capital Partners Dealers: Roth Capital Partners Use of proceeds: Working capital purposes | Nov 12, 2026 |
| Common stock on exercise of existing warrants Closed: US$4.03 a share · Warrants at US$4.03 for 60 months · Roth Capital Partners, LLC Dealers: Roth Capital Partners, LLC (lead) Use of proceeds: Working capital | Aug 13, 2026 |
| Private placement of unregistered shares of common stock (or pre-funded warrants) with common warrants Closed: US$4.03 a share · Warrants at US$4.03 for 60 months · Roth Capital Partners, LLC Dealers: Roth Capital Partners, LLC (lead) Use of proceeds: Working capital | Aug 13, 2026 |
| Shares under equity line of credit Announced: raise Buyers: Yorkville Advisors Global, LP (counterparty to $60 million equity line of credit; Aptevo may sell shares to it from time to time) Use of proceeds: Support ongoing clinical development, advance preclinical programs and fund general corporate purposes | Jan 9, 2026 |
| Registered direct offering of common stock or pre-funded warrants and common warrants Closed: US$8M raised · US$3.25 a share · Warrants at US$3.25 for 60 months · Roth Capital Partners Dealers: Roth Capital Partners (lead) Use of proceeds: Continued clinical development of product candidates, working capital and general corporate purposes | Jun 20, 2025 |
| Registered direct offering of common stock Closed: US$2M raised · US$0.862 a share · Roth Capital Partners Dealers: Roth Capital Partners (lead) Use of proceeds: Continued clinical development of product candidates, working capital and general corporate purposes | Apr 22, 2025 |
| Registered direct offering of common stock and warrants in concurrent private placement Closed: US$2.1M raised · US$1.19 a share · Warrants at US$1.19 for 60 months · Roth Capital Partners Dealers: Roth Capital Partners (lead) Use of proceeds: Continued clinical development of product candidates, working capital and general corporate purposes | Apr 4, 2025 |
| Warrant exercise of common stock upon exercise of existing warrants Announced: about US$6.2M · US$7.5 a share · Warrants at US$9.53 for 60 months · Roth Capital Partners Dealers: Roth Capital Partners Use of proceeds: Working capital and general corporate purposes | Dec 12, 2024 |